Debate: Should JAK Inhibitors use be Limited to Hydroxyurea-resistant/intolerant PV Patients? - No Published -- Download video MP4 360p Recommendations 47:55 Evaluating Current and Emerging Targeted Therapies in Hepatocellular Carcinoma 51:47 Updates in Front-Line Advances in Adjuvant and Targeted Treatment for Endometrial Cancer 09:30 Functional Pharmacist Analyzes Ivermectin: 2024 Update 39:26 What is Epigenetics? - with Nessa Carey 13:50 4 Tricks for when doctors gaslight you - Dr. Kaveh LIVE 04:51 PV: Clinical Use of Hydroxyurea 32:56 Colorectal Cancer and Immunotherapy with Dr. Van Morris 44:03 EGFR: The Challenge of Primary and Secondary Resistance 1:19:54 The 3 TOP Symptoms Of Long Covid & What You Need To Know To Protect Yourself | Dr. Leo Galland 53:54 Mitochondria - The Key To Disease and Mental Health with Dr. Martin Picard 27:52 Cancer Immunotherapy: 2020 Research Update and a Look Ahead with Dr. Padmanee Sharma 18:58 Jon G. Allen, PhD, on What We All Need to Know About Attachment 15:39 Understanding ADHD: Evolving Needs and Treatments 1:21:29 Sauna Benefits Deep Dive and Optimal Use with Dr. Rhonda Patrick & MedCram 1:43:06 Neuroscientist REVEALS How To COMPLETELY HEAL Your Body & Mind! | Caroline Leaf & Lewis Howes 29:49 The Truth About Complex PTSD and Essential Recovery Tools 1:01:57 Hemodynamic Aspects of Cardiogenic Shock: Case-Based Discussion (GUHA MD, BHIMARAJ MD ) Feb 15, 2018 02:54 PT-1 study update: addition of hydroxyurea to aspirin in essential thrombocythemia Similar videos 15:55 Debate: Should JAK Inhibitors use be Limited to Hydroxyurea-resistant/intolerant PV Patients? - Yes 20:53 Debate: Position of JAK2 inhibitors as second line therapy in Polycythemia vera 29:27 My view on current and future use of JAK inhibitors for ET, PV, and MF 23:39 Expert Perspectives: JAK Inhibitors for Polycythemia Vera 25:15 How to Manage Side Effects of JAK Inhibitors for Mylofibrosis in the Clinical Practice 07:17 Patients with Intolerance to Hydroxyurea 01:08 Dr. Mesa on Unanswered Questions Regarding JAK Inhibitors in Myelofibrosis 17:31 How Do You Treat PV Patients That Fail Hydroxyurea (HU)? 29:43 Expert Perspectives: JAK Inhibitors in Myeloproliferative Neoplasms 08:40 Managing Challenges with Traditional Treatments: Polycythemia Vera 33:02 Dr. John Mascarenhas, MD - PV Moving Beyond Hydroxyurea 16:29 Inadequate or Loss of Response to Ruxolitinib, and Combination Strategies 03:14 ASH: JAK Inhibitor Shows Promise in Myelofibrosis 1:34:09 JAK Inhibitors in Myelofibrosis: Expert Insights on Cases in Personalizing Therapy 46:46 Exploring the Role of JAK Inhibitors Across the Spectrum of IMIDs More results